Chromosomal Microarray Analysis (CMA) of Hematological Malignancies is now available through the Medical Genetics Laboratories at Baylor College of Medicine using a custom designed Heme/Onc Oligo array. The Medical Genetic Laboratories were the first to offer chromosomal microarray analysis for clinical application and we remain a leader in the implementation of new technology for whole genome analysis in clinical diagnostics. We offer a Heme/Onc Oligo array which consists of a high density custom DNA microarray specifically targeting 494 genes implicated in Leukemogenesis with 1 oligo per 7.5 kb covering the disease regions and backbone coverage at 78 kb resolution. The Heme/Onc Oligo array utilizes the latest array technology and genome knowledge to produce a diagnostic tool far superior to karyotype and/or FISH and represents a major advance in genomic profiling of hematological malignancies at high resolution. The Heme/Onc Oligo array will detect DNA abnormalities that would otherwise be missed by karyotype analysis or FISH.
Reasons for Referral:
The Heme/Onc OLIGO array may be ordered to identify unbalanced chromosomal rearrangements in patients with Acute leukemias, CLL, Multiple myeloma, Lymphomas, and Myelodysplastic syndrome (MDS). Patients found to have a deletion/duplication by the array will have the finding confirmed using chromosome analysis and/or FISH at no additional cost.
Testing Methodology:
The Heme/Onc OLIGO array (44K Oligo array) utilizes array-based comparative genomic hybridization (aCGH) with approximately 44,000 oligos (60mers) covering 494 known genomic locations. The disease gene regions have on average 1 oligo per 7.5 kb whereas the backbone regions have an average resolution of 1 oligo per 78 Kb. The backbone region is defined as the region between the disease gene minus the simple repetitive elements and low copy repeats. Genomic DNA from the test sample and a control sample are differentially labeled with fluorescent dyes and hybridized to the oligos. Results are analyzed using quantitative imaging methods and analytical software to assist in identifying each targeted-DNA sequence as loss of copy number (deletion), gain of copy number (duplication), or normal copy number. CMA is limited to detection of gains or losses of genomic material. It will not detect low level mosaicism, balanced translocations, inversions or point mutations that may be responsible for the clinical phenotype.
Specimen Requirements:
Blood or Bone Marrow in both EDTA (purple top) and Na Heparin (Green top) tubes:
Adult: 2-3 cc per
tube
Turnaround Time:
7-10
days
CPT Codes:
For information on fees or CPT Codes for
Heme/Onc CMA, please
contact our Billing Office at 713-798-3295.
Forms:
>> Cancer Cytogenetics Requisition
Educational and Informational Material:
>> Hem/Onc Array References:
-
Patel A, Kang SH, Lennon PA, Li YF, Rao PN, Abruzzo L, Shaw C, Chinault AC, Cheung SW. Validation of a targeted DNA microarray for clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia. Am. J. Hematol. 2007 Dec 27 [Epub ahead of print].
- Ou Z, Kang SH, Shaw CA, Carmack CE, White LD, Patel A, Beaudet AL, Cheung SW, Chinault AC. Bacterial artificial chromosome-emulation oligonucleotide arrays for targeted clinical array-comparative genomic hybridization analyses. Genet. Med. 2008 Apr; 10(4): 278-89.
Test Codes:
8690
|